Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-MVAC with or without panitumumab for first-line advanced urothelial carcinoma
2009-011882-10Phase 2Active
- Sponsor
- Unicancer
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab, methotrexate, vinblastine, doxorubicin and cisplatin in transitional cell carcinoma (TCC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival at 9 months. Started Jan 2010; status: active.
02
Drugs
panitumumabmethotrexatevinblastinedoxorubicincisplatin
03
Conditions
transitional cell carcinoma (TCC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2009-011882-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011882-10.